MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 74 filers reported holding MARINUS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,701,200 | -30.7% | 584,000 | -6.6% | 1.53% | -5.8% |
Q2 2023 | $6,787,500 | +28.6% | 625,000 | -18.3% | 1.62% | +2.7% |
Q1 2023 | $5,278,500 | +60.5% | 765,000 | -7.4% | 1.58% | +38.3% |
Q4 2022 | $3,288,276 | +887.5% | 826,200 | +1099.1% | 1.14% | +662.0% |
Q2 2022 | $333,000 | – | 68,900 | – | 0.15% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |